Form 4: Evoke Pharma Director Cashes Out Options Post-Merger

Evoke Pharma Director Vickie S. Reed converted all outstanding stock options into cash following the company's merger with QOL Medical, LLC.

Summary

• Vickie S. Reed, a Director of Evoke Pharma Inc. (EVOK), reported a change in beneficial ownership.
• The transaction occurred on December 17, 2025, coinciding with the effective time of a merger.
• Evoke Pharma Inc. merged with QOL Medical, LLC ('Parent') and QOL-EOS Merger Sub, Inc., resulting in Evoke Pharma becoming a wholly-owned subsidiary of Parent.
• Immediately prior to the merger's effective time, all outstanding stock options held by Ms. Reed were accelerated, fully vested, canceled, and converted into a cash payment.
• The cash payment for each option was calculated as the aggregate number of shares underlying the option multiplied by the difference between $11.00 and the option's per-share exercise price.
• Ms. Reed disposed of 1,250 stock options with an exercise price of $5.41, 5,833 stock options with an exercise price of $4.45, and 1,250 stock options with an exercise price of $3.453.
• The total cash received by Ms. Reed from these option conversions amounted to approximately $54,656.40.

Sentiment

Score: 7

Explanation: Neutral to slightly positive for the reporting person as they realized a cash gain from their options due to the merger. For the company, it signifies the completion of a strategic event (merger).

Positives

• Director Vickie S. Reed realized a cash gain from the conversion of her stock options.
• The merger provided a clear exit strategy and liquidity for option holders, with options becoming fully vested and accelerated.
• The cash payout mechanism ensured that option holders benefited from the merger consideration.

Negatives

• The reporting person no longer holds beneficial ownership of Evoke Pharma stock options.
• Evoke Pharma Inc. is now a wholly-owned subsidiary, meaning its common stock is no longer publicly traded.

Future Outlook

The filing indicates the completion of a merger where Evoke Pharma Inc. became a wholly-owned subsidiary of QOL Medical, LLC, suggesting its future operations will be integrated under the parent company.

Industry Context

This transaction reflects a common outcome in mergers and acquisitions where outstanding equity awards of the acquired company are converted into cash or equivalent securities of the acquiring entity. It signifies the completion of a strategic consolidation within the pharmaceutical or biotech sector, with Evoke Pharma transitioning from a public to a private entity under QOL Medical, LLC.

Comparison to Industry Standards

• The $11.00 per share merger consideration and the method of cashing out options are standard practices in M&A transactions.
• The acceleration and cash conversion of options are typical provisions to ensure executive and director compensation is settled upon a change of control during an acquisition.

Corporate Governance

Stakeholder Impact

• Shareholders: Public shareholders of Evoke Pharma Inc. would have received the merger consideration of $11.00 per share.
• Option Holders: Option holders, such as Director Vickie S. Reed, received cash for their vested options, providing liquidity.
• Employees: While not detailed in this filing, mergers typically impact employees through integration processes and potential changes in compensation or roles.

Key Dates

Keywords

Evoke Pharma, EVOK, Form 4, Insider Transaction, Stock Options, Merger, Acquisition, QOL Medical, Beneficial Ownership, Director Compensation